SCHEMBL24643275

SCHEMBL24643275

CON(C)C(=O)CN(Cc1cccc(F)c1Br)C(=O)OC(C)(C)C

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SSTR4 P31391 1/20 0.38
RIPK1 Q13546 2/20 0.36
ALDH1A1 P00352 2/20 0.33
MAPT P10636 2/20 0.32
TP53 P04637 1/20 0.32
TSPO P30536 1/20 0.31
KDM4E B2RXH2 1/20 0.31
HDAC1 Q13547 2/20 0.31
HDAC3 O15379 1/20 0.31
HDAC2 Q92769 1/20 0.31
NCOR2 Q9Y618 1/20 0.31
AKT1 P31749 1/20 0.31
MTNR1A P48039 1/20 0.31
MTNR1B P49286 1/20 0.31
CTSS P25774 2/20 0.30
CTSK P43235 1/20 0.30
CTSL P07711 1/20 0.30
CTSB P07858 1/20 0.30
MEN1 O00255 1/20 0.30
KMT2A Q03164 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31597762 0.80 SSTR4 (0.36) SSTR4ALDH1A1MAPTKDM4EMTNR1A
SCHEMBL30697111 0.80 RIPK1 (0.48) SSTR4RIPK1ALDH1A1KDM4ECTSS
SCHEMBL2900197 0.78 KDM1A (0.42) SSTR4RIPK1MAPTTP53TSPO
SCHEMBL20563933 0.72 RIPK1 (0.38) RIPK1ALDH1A1MAPTHDAC1HDAC6
SCHEMBL24643278 0.72 MEN1 (0.37) ALDH1A1KDM4EMEN1KMT2APDCD1
SCHEMBL21257824 0.71 ALDH1A1 (0.36) SSTR4RIPK1ALDH1A1HDAC1HDAC3
SCHEMBL24443453 0.71 HDAC6 (0.34) HDAC1HDAC2MEN1KMT2AHDAC6
SCHEMBL23257905 0.70 GYS1 (0.42) RIPK1ALDH1A1TSPOKDM4EHDAC1
SCHEMBL3913733 0.70 HDAC6 (0.33) HDAC1HDAC2HDAC6
SCHEMBL2891918 0.69 KDM1A (0.38) RIPK1HDAC1HDAC3HDAC2NCOR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240262847-A1 COVALENT RAS INHIBITORS AND USES THEREOF WILMINGTON TRUST, NATIONAL ASSOCIATION, AS AGENT 2024-08-08 US disclosed
EP-4334324-A1 COVALENT RAS INHIBITORS AND USES THEREOF Revolution Medicines, Inc. (US) 2024-03-13 EP disclosed
WO-2022235866-A1 COVALENT RAS INHIBITORS AND USES THEREOF Revolution Medicines, Inc. (US) 2022-11-10 WO disclosed
WO-2022235866-A1 COVALENT RAS INHIBITORS AND USES THEREOF Revolution Medicines, Inc. (US) 2022-11-10 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240262847-A1 COVALENT RAS INHIBITORS AND USES THEREOF KRAS, NRAS, HRAS SSTR4 4143/4885RIPK1 801/4885ALDH1A1 3445/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.